2023 Drug Safety Communications
Current Drug Safety Communications More Drug Safety Communications
- 11-28-2023: FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
- 5-11-2023: FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
- 4-13-2023: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use